Drug GMP Import Bans in Brief
This article was originally published in The Gold Sheet
Two firms in China and one each in India and the United Kingdom lost access to EU markets because of GMP issues in the past two months. Meanwhile six firms lost access to the U.S. market either because of GMP problems FDA inspectors found or because they refused FDA inspections.
Register for our free email digests: